Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/sextrans-2020-054835 | DOI Listing |
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFBackground: Human pluripotent stem cell (hPSC)-derived brain organoids patterned towards the cerebral cortex are valuable models of interactions occurring in vivo in cortical tissue. We and others have used these cortical organoids to model dominantly inherited FTD-tau. While these studies have provided essential insights, cortical organoid models have yet to reach their full potential.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with neuroinflammation and heightened production of reactive oxygen species (ROS) in the brain from overactive NADPH Oxidase 2 (NOX2). The current study examines whether administration of a novel, brain-penetrant NOX2 inhibitor (CPP11G & CPP11H) reduces amyloid plaque load and improves AD-associated vascular dysfunction in a male APP-PS1 mouse model of AD.
Method: Intraperitoneal injections of CPP11G (n = 1) or CPP11H (n = 2) three times per week began at 9-10 months of age in the treatment APP-PS1 group (15 mg/kg).
Alzheimers Dement
December 2024
Samford University McWhorter School of Pharmacy, Birmingham, AL, USA.
Background: Despite some advances in treatment, a cure for Alzheimer's disease (AD) remains elusive. Disease hallmarks include heightened neuroinflammation and oxidative stress, associated with progressive decline in mobility and cognitive functions. Natural compounds provide a valuable reservoir of novel bioactive substances with therapeutic potential, fewer side effects, and increased affordability.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Nairobi, Nairobi, Nairobi, Kenya.
Background: The recruitment of individuals for Alzheimer's disease (AD) genetic studies particularly those with low socioeconomic status, and living in rural areas remains a challenge in Sub-Saharan Africa (SSA), due to stigma-related cultural beliefs that hinder their participation. The Recruitment and Retention of Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD - ADSP) project is a case-control genetic epidemiological study involving individuals who are living with AD and disease - free healthy control individuals. The aim is to build a resource that greatly expands Alzheimer's disease genetic studies in the currently underrepresented African ancestry populations and Hispanic/Latinx individuals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!